REMEGEN CO. LTD YC 1 - Asset Resilience Ratio
REMEGEN CO. LTD YC 1 (REG) has an Asset Resilience Ratio of 16.77% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2025–2025)
This chart shows how REMEGEN CO. LTD YC 1's Asset Resilience Ratio has changed over time. See financial agility of REMEGEN CO. LTD YC 1 to measure the company's free cash flow as a share of total liabilities.
Liquid Assets Composition Over Time
This chart breaks down REMEGEN CO. LTD YC 1's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see REG market cap.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 0% |
| Short-term Investments | €1.22 Billion | 16.77% |
| Total Liquid Assets | €1.22 Billion | 16.77% |
Asset Resilience Insights
- Good Liquidity Position: REMEGEN CO. LTD YC 1 maintains a healthy 16.77% of assets in liquid form.
- This level provides good financial flexibility while maintaining productive asset deployment.
- The company has significant short-term investments, indicating active treasury management.
REMEGEN CO. LTD YC 1 Industry Peers by Asset Resilience Ratio
Compare REMEGEN CO. LTD YC 1's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
GENMAB AS SP.ADR/1/10DK 1
F:GE91 |
Biotechnology | 0.00% |
|
Abivax SA
PA:ABVX |
Biotechnology | 2.34% |
|
NewAmsterdam Pharma Company N.V. Ordinary Shares
NASDAQ:NAMS |
Biotechnology | 20.92% |
|
Ligand Pharmaceuticals Incorporated
NASDAQ:LGND |
Biotechnology | 43.36% |
|
Hebei Changshan Biochem Pharma
SHE:300255 |
Biotechnology | -0.03% |
|
Zhejiang Ausun Pharmaceutical Co Ltd
SHG:603229 |
Biotechnology | 0.12% |
|
Chengdu Kanghua Biological Products
SHE:300841 |
Biotechnology | 1.19% |
|
PYC Therapeutics Ltd
AU:PYC |
Biotechnology | 83.51% |
Annual Asset Resilience Ratio for REMEGEN CO. LTD YC 1 (2025–2025)
The table below shows the annual Asset Resilience Ratio data for REMEGEN CO. LTD YC 1.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 16.77% | €1.22 Billion ≈ $1.42 Billion |
€7.25 Billion ≈ $8.47 Billion |
-- |
About REMEGEN CO. LTD YC 1
RemeGen Co., Ltd., a biopharmaceutical company, discovers, develops, produces, and commercializes biological drugs for the treatment of autoimmune, oncology, and ophthalmic diseases in Mainland China and the United States. The company offers Telitacicept (RC18) for the treatment of systemic lupus erythematosus (SLE) autoimmune disease, rheumatoid arthritis, and myasthenia gravis; and Disitamab Ve… Read more